Skip to main content
Hospital Pharmacy logoLink to Hospital Pharmacy
. 2019 Nov 18;56(4):228–234. doi: 10.1177/0018578719888913

Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration

Margaux Vallée 1, Isabelle Barthélémy 2, Mihaela Friciu 3, Élaine Pelletier 4, Jean-Marc Forest 4,, France Benoit 5, Grégoire Leclair 3
PMCID: PMC8326865  PMID: 34381254

Abstract

Objective: To test the compatibility of intravenous (IV) lactated Ringer’s injection (LR) with 94 injectable (IV) drugs during simulated Y-site administration. Methods: Ninety-four IV drugs were investigated for compatibility with LR (Baxter). Each sample was prepared in duplicate and performed at room temperature. Two observers performed visual evaluation independently immediately upon mixing and then 15 minutes, 1 hour, 2 hours, 3 hours, and 4 hours after admixture. Another observer performed a particle counting test on 1 of the 2 duplicates of each admixture that did not immediately show incompatibility and then after 4 hours by a light obscuration particle count test. Results: Of the 94 tested drugs, 86 were found to be compatible with LR. A total of 8 drugs were found to be physically incompatible. Of these incompatible drugs, 7 were directly identified visually and 1 was confirmed by the light obscuration particle count test. Conclusion: Lactated Ringer’s injection was physically compatible for 4 hours with 86 tested drugs during simulated Y-site administration. Eight drugs, ciprofloxacin, cyclosporine, diazepam, ketamine, lorazepam, nitroglycerin, phenytoin, and propofol, were found to be incompatible and should not be administered with LR.

Keywords: lactated Ringer’s injection, compatibility, Y-injection site

Introduction

Lactated Ringer’s injection (LR) is a sterile, nonpyrogenic solution that may be used for intravenous (IV) irrigation, washing, and rinsing and also acts as a diluent for infusion of drugs. Lactated Ringer’s injection contains sodium chloride (Na+ 130 mEq/L), potassium chloride (K+ 4 mEq/L), calcium chloride (Ca+ 3 mEq/L), chloride (Cl 109 mEq/L), and lactate (28 mEq/L) in water for injection. 1

Questions about drug compatibility are recurrent, and bringing up available information is an essential part of pharmacist assignment. Lactated Ringer’s injection is widely used in Sainte-Justine University Teaching Hospital, especially for patients receiving many other IV drugs by Y-site administration. Compatibility data about LR are scarce, and there is a need to evaluate the Y-site injection compatibility of LR with other IV drugs.

The purpose of this study was to determine Y-site injection compatibility of LR with 94 IV drugs using visual evaluation and light obscuration particle counting.

Methods

Lactated Ringer’s injection (lot W5I17C2) was provided by Baxter in 250 mL bags. A selection of 94 drugs was tested with LR. Details about the tested drugs and concentration are provided in Table 1. Tested IV drugs were reconstituted according to the manufacturer’s recommendation when required.

Table 1.

Drugs Tested for Physical Compatibility With Lactated Ringer’s Injection (Baxter) in Simulated Y-site Injection Administration After Visual Inspection and Light Obscuration Particle Count Test.

Drug name Particle count test
Visual
Concentration mg/mL (or as specified) Manufacturer Lot Concentration mg/mL Manufacturer Lot
1 Acetazolamide sodium 100 Sterimax 01000A15
01000B15A
100 SteriMax 01000B11
2 Acetylcysteine 200 Alveda Pharma 14055056 200 Alveda Pharma 9075059
3 Acyclovir sodium 50 PPC 6008872 50 PPC 6002138
4 Albumin, human (Alburex-25) 250 CSL Behring 4309900011 250 CSL Behring 4309900011
5 Amikacin sulfate 250 Sandoz EZ9666 250 Sandoz BR9068
6 Aminophylline 25 Hospira 54-375-DK 50 Omega OK472
7 Amiodarone hydrochloride 50 Sandoz FJ2260 50 Sandoz BR5023
8 Amphotericin B liposomal 4 Astellas 20160416074 4 Bristol-Myers Squibb 93070TB31
9 Amphotericin B deoxycholate 5 Bristol-Myers Squibb 51940TB24 5 Bristol-Myers Squibb 51940TB24
10 Ampicillin sodium 100 Novopharm FF7340
DS8980
100 Novopharm BP1879
11 Atropine sulfate 0.4 Alveda Pharma 50587 0.4 Alveda Pharma 434
12 Azithromycin 500 Sterimax 7602823
7602657
500 Pfizer Z065606
13 Bretylium tosylate 50 Sandoz EF9361 50 Sandoz AY2120
14 Bupivacaine hydrochloride 0.5% Hospira 48-198-DK 20 mL Hospira 48-198-DK
15 Caffeine citrate 10 Sandoz EM6977 10 Sandoz BR2092
16 Calcium gluconate 100 Fresenius Kabi 6010000 100 PPC 6001828
17 Calcium chloride 100 Hospira 52-393-DK
42-315-DK
100 Hospira 89458DK
18 Caspofungin acetate 5 Merck 2195750 5 Merck 2070040
19 Cefazolin sodium 100 Hospira 117F003 100 Hospira 117B004
20 Cefotaxime 100 Sterimax 4CS1513CA
4CS1512CA
100 Sanofi 91846
21 Cefoxitin 100 Novopharm 0001D5 100 Hospira 123B002
22 Ceftazidime 100 PPC 105394C 100 PPC 103573C
23 Ceftriaxone sodium 100 Hospira H101HC4
H103HC4
100 Hospira 120B001
24 Cefuroxime 100 Sterimax 157012.1 100 PPC 8309
25 Chlorpromazine hydrochloride 25 Sandoz EF2262
DL5599
25 Sandoz AY5529
26 Ciprofloxacin 2 Hospira 50672 2 Hospira 4777201
27 Clindamycin phosphate 150 Sandoz FJ8765 150 Sandoz CS5861
28 Cloxacillin sodium 100 Sterimax 2CL1531CA 100 Novopharm BP5356
29 Cyclosporine 50 Novartis S0076
S0070
50 Novartis S0065
30 Dexamethasone sodium phosphate 4 Sandoz FM3580 4 Sandoz F20120216057
31 Dexmedetomidine hydrochloride 0.1 Hospira 67-294-DK
63-198-DK
0.100 Hospira 67-294-DK
63-198-DK
32 Dextrose 50% 500 Hospira 50-239-DK 500 Hospira 03399DK
33 Diazepam 5 Sandoz 350085
429070
5 Sandoz BP9416
34 Digoxin 0.25 Sandoz FG7843 0.05 Sandoz BK4807
35 Dimenhydrinate 10 Sandoz FL9838
ES0313
10 Sandoz CB8792
36 Diphenhydramine hydrochloride 50 Sandoz 4K152
EJ5196
50 Sandoz CC6193
37 Dobutamine hydrochloride 12.5 Hospira 57-245-DK
61-123-DK
12.5 Sandoz BT5348
38 Dopamine hydrochloride 3,2 Baxter P331496 3.2 Baxter 2BO846
39 Enalaprilat 1.25 Sterimax 143177.1 1.25 Sandoz CB8013
40 Epinephrine hydrochloride 1 Erfa F5E195 1 Hospira 107388E10
41 Erythromycin lactobionate 50 Amdipharm 44-906-TB-24 50 Amdipharm 88324TB26
42 Esmolol hydrochloride 10 Baxter 115376Z 10 Baxter 071310Z
43 Fentanyl citrate 0.050 Sandoz FU61144 0.050 Sandoz CD0281
44 Fluconazole 2 Sandoz EG3097 2 Sandoz BX9809
45 Furosemide 10 Omega 5J082 10 Sandoz BY8329
46 Gentamicin sulfate 10 Sandoz EZ8736
EW0069
40 Sandoz BU6761
47 Granisetron hydrochloride 1 Omega 4M838 1 Omega 4M838
48 Haloperidol lactate 5 Sandoz GB9093
FS6939
FM6054
5 Sandoz GB9093
FS6939
FM6054
49 Heparin sodium 1000 IU/mL Sandoz FU4871 1000 IU/mL PPC 6000130N
50 Hydralazine hydrochloride 20 Sterimax PLNG1518
PLNK1438
PLNK1440
20 Novartis 00501B10
51 Hydrocortisone sodium succinate 50 Novopharm 0480514
4160115
50 Novopharm 9650310
52 Hydromorphone hydrochloride 10 Sandoz FA1043 10 Sandoz CC7651
53 Hydroxyzine hydrochloride 50 Sandoz EF1703 N/A N/A N/A
54 Insulin regular (Humulin R) 100 IU/mL Lilly C358890H
C358890K
100 IU/mL Lilly C001867D
55 Isoproterenol hydrochloride 0.2 Sandoz FM8982 0.2 Sandoz BU3292
56 Ketamine hydrochloride 50 Sandoz FB4018
FK2313
50 Sandoz BX2917
57 Labetalol hydrochloride 5 Sandoz FD6396 5 Sandoz BW9642
58 Lidocaine hydrochloride 1% Alveda Pharma 15262021 1 AstraZeneca 10410
59 Linezolid 2 Pfizer 3770714 2 Pfizer 3770714
60 Lorazepam 4 Hospira 53275EV
52170EV
4 Sandoz CZ3827
61 Magnesium sulfate 500 Fresenius Kabi 6010611 500 PPC 6101127
62 Mannitol 250 Hospira 60-222-DK 250 Hospira 01485DK
63 Meropenem 50 Sterimax 2694106 50 AstraZeneca JD947
64 Methylprednisolone sodium succinate 62.5 Novopharm 6000215
4450915
62.5 Pfizer G00030
65 Metoclopramide hydrochloride 5 Sandoz EM2979
EL7926
EL4390
EG3207
FG3415
5 Sandoz BY4533
66 Metronidazole 5 Hospira 58-011-JT 5 Hospira 7811853
67 Midazolam hydrochloride 5 Fresenius Kabi 6009861 5 PPC CB8867
68 Milrinone lactate 1 Sandoz FH8172 1 Sandoz CB2379
69 Morphine sulfate 50 Sandoz FC1902 50 Sandoz BR8368
70 Multivitamins (Multi-12/K1 pediatric) Sandoz FL5796
(vial 1)
FL6371
(vial 2)
Sandoz CY0799
et CY0797
71 Multivitamins (Multi-12) Sandoz FL5795
(vial 1)
FK1211
(vial 2)
Sandoz CG5111
72 Naloxone hydrochloride 0.4 Alveda Pharma 30209
30522
0.4 Sandoz BL1147
73 Nicardipine hydrochloride 0.2 Baxter NC096925 0.2 Baxter NC096925
74 Nitroglycerin 5 Omega 5GO44
5D948
5 Omega 1K775
75 Norepinephrine bitartrate 1 Sandoz FD2438 1 Sandoz BU3181
76 Octreotide acetate 0.500 Omega 5F008
5J086
0.500 Omega S0013
77 Oxytocin 10 IU/mL Hospira 521388E01 10 IU/mL Hospira 054528E01
78 Penicillin G sodium 500 000 IU/mL Fresenius Kabi 303246 100 000 IU/mL Novopharm CG7189
79 Phenytoin sodium 50 Sterimax 152079.1 50 Sandoz CJ8539
80 Piperacillin sodium 200 Hospira 1P301MC3 200 Mayne Pharma 1P301MC1
81 Piperacillin sodium / Tazobactam 200 Sandoz 20160428083 200 Sandoz BW5243
82 Potassium chloride 2 mEq/mL Hospira 50-151-DK 2 mEq/mL Hospira 92180DK
83 Potassium phosphate 3 mmol/mL Sandoz 6109697 3 mmol/mL Sandoz BW8396
84 Propofol 10 Pharmascience A050374 10 Novopharm R10167B
85 Ranitidine hydrochloride 25 Sandoz F59330
FW1356
25 GlaxoSmithKline C566822
86 Rocuronium bromide 10 Sandoz FS6942
FM5396
10 Hospira 12008DK
87 Salbutamol 1 GlaxoSmithKline V972 1 GlaxoSmithKline L061
88 Sodium bicarbonate 1 mEq/mL Hospira 54-178-EV 1 mEq/mL Abbott 11138DK
89 Sodium nitroprusside 25 Hospira 531303A 25 Omega 1K775
90 Tobramycin sulfate 40 Sandoz 6009024 40 Sandoz C152865
91 Trimethoprim / Sulfamethoxazole 16/80 GlaxoSmithKline 20160422036 16/80 GlaxoSmithKline 1E531
92 Vancomycin hydrochloride 50 Sandoz FF5576
FW3816
50 Hospira 096588E02
93 Verapamil hydrochloride 2.5 Sandoz FM1440 2.5 Sandoz CM0627
94 Voriconazole 10 Sandoz FY0203 10 Sandoz FY0203

Ninety-four drugs were tested in 1:1 admixture with LR in testing glass tubes at room temperature and under normal room light. Each drug available in a breakable glass ampoule was passed through a 5-µm filter as it was introduced into the testing glass tube.

Step 1: Visual evaluations were performed independently by 2 observers in accordance with the established procedure previously reported several times.2-8 Visual simulated Y-site injection evaluation was accomplished by the 2 observers by mixing 1 mL of LR with 1 mL of the tested drug in glass tube and then switching the order of drug mixing for the second observation. Each admixture was visually observed immediately upon mixing and then at specified time points: 15 minutes, 1 hour, 2 hours, 3 hours, and 4 hours. Visual compatibility was defined as the absence of any color change or visible particle matter, gas bubble, substantial haze, or precipitate by a naked eye.

Step 2: Another second observer performed the light obscuration particle count test using the LS-20 Liquid Particle Counter (Lighthouse Worldwide Solutions, Medford, OR). At the beginning of the experiment, the particle count test was controlled by a standardized solution (Pharm-Trol Particle Count Control solution; Thermo Scientific, Saint-Laurent, QC, Canada, lot 44035) with a specific concentration of 15 µm particles. This allowed us to ascertain that the accuracy of the particle counter is in agreement with the United States Pharmacopeia (USP) Reference Standard for the duration of the observations. Furthermore, on each day of observation, a control solution made of 10 mL of LR and 10 mL of sterile water for injection passed both the visual test and the particle count test immediately upon mixing and after 4 hours. Then each admixture was tested in sterile plastic syringes by mixing 10 mL of LR with 10 mL of the tested drug. In the absence of visual incompatibility, the particle content of the first admixtures was immediately analyzed and that of the second was quantified by a final particle count test at 4 hours. Admixtures that were visually incompatible were immediately discarded without particle count test evaluation. Drug admixtures were considered compatible if the average number of particles did not exceed USP <788> Test 1.B guidelines. 9 In this study, volumes are less than 100 mL, and the limit allowed for particulate matter does not exceed 6000 particles ≥10 µm and 600 particles ≥25 µm per container. Thus, with a container volume of 20 mL, 5 mL per test, the average number of particles equal to or greater than 10 µm does not exceed 300 particles and no more than 30 particles equal to or greater than 25 µm to be considered compatible. Each measure was in triplicate, 3 times 5 mL, with 4 mL as a prime.

Results

A total of 94 admixtures were visually inspected in step 1, and 77 of them demonstrated no evidence of visual incompatibility immediately and throughout the 4-hour period. Seventeen drugs were described as being possibly or definitively incompatible with LR when inspected visually by 2 different observers. Table 2 illustrates the details associated with the 17 admixtures that could possibly be visually incompatible.

Table 2.

Incompatibilities of Lactated Ringer’s Injection With Other Drugs After Visual Inspection by the 2 Observers in Step 1.

Drug name Notes
1 Amiodarone Uncertain
2 Caspofungin Uncertain
3 Ciprofloxacin Incompatible
4 Clindamycin Uncertain
5 Cyclosporine Precipitate
6 Diazepam Immediate precipitate
7 Insulin (human regular)
(Humulin R)
Uncertain
8 Ketamine Incompatible
9 Lorazepam Incompatible
10 Methylprednisolone Uncertain
11 Multivitamins (adult)
(Multi-12)
Uncertain
12 Multivitamins (pediatric)
(Multi-12/K1 pediatric)
Uncertain
13 Nitroglycerin Uncertain
14 Penicillin G Uncertain
15 Phenytoin Incompatible
16 Propofol Precipitate
17 Verapamil Uncertain

In step 2, just before the light obscuration particle count test, 7 admixtures showed precipitation (ciprofloxacin, cyclosporine, diazepam, ketamine, lorazepam, phenytoin, propofol) and were discarded without particle count test evaluation because there is evidence of incompatibility. All the other 10 admixtures that were suspected to be visually incompatible and did not clearly precipitate were analyzed by the particle count test, including all the other 77 certain results by visual inspection, to determine whether they were really compatible or not. For 86 drugs, measurement of the number of particles ≥25 and ≥10 µm was within specification limit immediately upon admixture and after 4 hours. Only for 1 drug, nitroglycerin, particle counting and sizing confirmed the incompatibility suspected (Table 3).

Table 3.

Incompatibilities of Lactated Ringer’s Injection With Other Drugs After Step 2 With Light Obscuration Particle Count Test.

Drug name Notes
1 Nitroglycerin >30 × 25 µm particles/mL at T = 0

In summary, all the incompatible drugs are listed in Table 4, with the corresponding reason.

Table 4.

Incompatibilities of Lactated Ringer’s Injection With Other Drugs After All Analyses.

Drug name Incompatibility reason
1 Ciprofloxacin Directly by visual inspection
2 Cyclosporine Directly by visual inspection
3 Diazepam Directly by visual inspection
4 Ketamine Directly by visual inspection
5 Lorazepam Directly by visual inspection
6 Nitroglycerin Especially with light obscuration particle count test
7 Phenytoin Directly by visual inspection
8 Propofol Directly by visual inspection

Discussion

Lactated Ringer’s injection is widely used as a drug diluent. Until now, no study has evaluated specifically the compatibility of LR with drugs used in clinical practice. This study tested the compatibility of LR with 94 injectable drugs.

The simulated Y-site injection model used in this study is based on the model described by Allen et al in 1977. They established that when mixing 2 solutions in a Y-administration set, the concentration ratio will be 1:1. 10 As admitted, if 2 drugs are compatible at high concentration, they will also probably be compatible at lower concentrations. 11 This hypothesis reflects the condition in Y-site administration that is used by nurses during drug administration.

Results by visual control show that 10 drugs are possibly incompatible with LR, whereas 7 are incompatible after visual test. Visual control can only detect particles greater than 50 µm, whereas the light obscuration particle count test assesses particle within the range of 1 to 50 µm and permits to comply with USP <788> Test 1.B. 9 This could explain the difference seen between the results of the 2 testing methods. This is why the results obtained with the particle count test are more reliable than those obtained by visual control. However, when admixture leads to an obvious precipitation, the particle count test is not processed, thus becoming useless.

Precipitate formation occurred when propofol was mixed with LR. Because propofol is an opaque white emulsion, particle count test could not be performed due to its dense turbidity. Propofol would require an alternative approach to physical compatibility other than particle count test evaluation.

Concerning cyclosporine and nitroglycerin, the present results are not congruent with published data.12-14 These 2 drugs are listed as compatible with LR in some visual studies12,13 where physical compatibility was evaluated only by the absence of changes in measured haze or turbidity, particulates, or color found. The light obscuration particle count test was required to detect an incompatibility like in this study. Cyclosporine needs to be diluted to a concentration of 5 mg/mL or less using sterile water before testing with light obscuration particle count test because the 50 mg/mL solution is too viscous for particle count test analysis and even more diluted for clinical practice.2,14 The dilution factor used could explain the difference between other data because a drug could be incompatible at high concentration but be compatible, almost for 4 hours, after being diluted. Nitroglycerin incompatibility with LR could be detected by the light obscuration particle count test, depending on techniques used by other authors, which could explain the conflicting result.

Surprisingly, compatibility results were found with drugs such as ceftriaxone, amphotericin B (Fungizone), and piperacillin sodium/tazobactam that are supposed to be incompatible according to published data.14-18 Several factors may explain these differences as contact time, methods, concentrations, diluents, manufacturers, and excipients. Lack of recent studies for these drugs makes the result obtained with a modern particle counting test confident to be trusted.

All other results of this study are consistent with the results of previous compatibility studies and demonstrate the value of the light obscuration particle count test to assess compatibility between 2 drugs and complete visual inspection, eliminating hazardous results. Lactated Ringer’s injection and each other drug were tested at 1 concentration, and it is possible that the incompatible combinations might be compatible when mixed at lower concentrations.

Conclusion

Lactated Ringer’s injection was compatible with 86 of the drugs tested and was found to be directly incompatible by naked eye with ciprofloxacin, cyclosporine, diazepam, ketamine, lorazepam, phenytoin, and propofol and additionally by light obscuration particle count test with nitroglycerin. The light obscuration particle count test to assess compatibility between 2 drugs completes visual inspection, eliminating hazardous results.

Footnotes

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD: Jean-Marc Forest Inline graphic https://orcid.org/0000-0001-8451-5471

References

  • 1. National Center for Biotechnology Information (US). PubChem Compound Database; CID = 56841910 (Ringer’s lactate solution). Bethesda, MD: National Center for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/56841910#section=Top. Accessed October 5, 2016. [Google Scholar]
  • 2. Sullivan T, Forest J-M, Leclair G. Compatibility of cloxacillin sodium with selected intravenous drugs during simulated Y-site administration. Hosp Pharm. 2015;50(3):214-220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Ferreira E, Forest J-M, Hildgen P. Compatibilité du dimenhydrinate injectable pour l’administration en Y. Pharmactuel. 2004;37(1):17-20. [Google Scholar]
  • 4. Péré H, Chassé V, Forest J-M. Compatibilité du pantoprazole injectable lors d’administration en Y. Pharmactuel. 2004;37:193-196. [Google Scholar]
  • 5. Pelletier Forest ÉJ-M, Hildgen P. Compatibilité de la kétamine injectable lors de l’administration en dérivé avec d’autres médicaments usuels. Pharmactuel. 2006;39:71-75. [Google Scholar]
  • 6. Pelletier E, Forest J, Hildgen P. Compatibilité des mélanges de morphine et de kétamine ou d’hydromorphone et de kétamine injectables lors de leur administration en dérivé avec d’autres médicaments usuels. Pharmactuel. 2007;40(2):23-27. [Google Scholar]
  • 7. Tollec S, Touzin K, Pelletier E, Forest J-M. Évaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel. 2013;46(1):6-21. [Google Scholar]
  • 8. Legris M-E, Lavoie A, Forest J-M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel. 2015;47(3):67-172. [Google Scholar]
  • 9. The United States Pharmacopeia. Particulate matter in injections. Rockville, MD: United States Pharmacopeia; 2019. [Google Scholar]
  • 10. Allen LV, Levinson RS, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection sites of intravenous administration sets. Am J Hosp Pharm Sept. 1977;34(9):93943. [PubMed] [Google Scholar]
  • 11. Trissel LA. Handbook on Injectable Drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2003. [Google Scholar]
  • 12. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral Compatibility): Lactated Ringer’s injection—cyclosporin compatibility detail. http://www.micromedexsolutions.com. Accessed October 18, 2018.
  • 13. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral Compatibility): Lactated Ringer’s injection—nitroglycerin compatibility detail. http://www.micromedexsolutions.com. Accessed October 19, 2018.
  • 14. Trissel LA, Leissing NC. Trissel’s Tables of Physical Compatibility. Lake Forest, IL: Multimatrix, Inc; 1996. [Google Scholar]
  • 15. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral Compatibility): Lactated Ringer’s injection—ceftriaxone compatibility detail. http://www.micromedexsolutions.com. Accessed October 21, 2018.
  • 16. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral compatibility): Lactated Ringer’s injection—phenytoin compatibility detail. http://www.micromedexsolutions.com. Accessed October 24, 2018.
  • 17. Truven Health Analytic’s: Trissel’s 2 clinical pharmaceutics database (Parenteral Compatibility): Lactated Ringer’s injection—fungizone compatibility detail. http://www.micromedexsolutions.com. Accessed October 21, 2018.
  • 18. Truven Health Analytics: Trissel’s 2 clinical pharmaceutics database (Parenteral compatibility): Lactated Ringer’s injection—Sulfamethoxazole-trimethoprim compatibility detail. http://www.micromedexsolutions.com. Accessed November 11, 2018.

Articles from Hospital Pharmacy are provided here courtesy of SAGE Publications

RESOURCES